EBITDA of SEK 69m, below ABGSCe due to project timingOwn production better, we raise '23e EBITDA by ...
Redeye ger en initial kommentar om den fullständiga Donanemab-datan samt förslaget från CMS om breda...
• Q2 report due on Thursday, 17 August • Non-woven in high gear, FW likely to struggle • NWC release...
OrderYOYO announced on Tuesday, July 18th, the company’s performance during Q2-23.
IRLAB Therapeutics has provided an update on its ongoing Phase IIb clinical trial for pirepemat, whi...
Redeye is encouraged to learn that Initiator Pharma has obtained positive data from its phase I drug...
Amid 1) a hiccup in its turnaround; 2) a shift in the investor base; and 3) low liquidity in the sha...
Redeye comments on Arise’s Q2 report, which came in better than expected.
Cibus posted Q2 net operating income of EUR 28.1m, up 11% y/y on the back of acquisitions and in lin...
Redeye provides an initial take on Enzymatica’s Q2 2023 report.
Vaisala revised its net sales guidance and reduced its EBIT expectations for 2023.
Redeye states that adjusted EBITDA came in above Redeye's estimates but that sales was just below es...
• Better-than-expected Q2 report, mainly driven by Public DK • We raise our EBIT estimates on lower ...
• Adj. EBITDA SEK -5m vs. ABGSCe SEK 1m • Cash of SEK 20m and an unused credit facility of SEK 20m •...
Redeye retains its positive view of Proact following a solid Q2 report, with the positive highlights...
Redeye expected higher sales in Q2, and so did Bong as well.
Stigande räntekostnader pressar vinsten och nu ligger fokus på att stärka likviditeten.
Orderingången nådde nytt rekord.. Drivet av Westermo och delvis beroende på en engångsorder på 100 ...
Bra resultat givet utmanande förutsättningar Bokusgruppen rapporterade EBITA på -23,5 mkr, att jämfö...
Tre nya avtal Rörelseresultat för kvartalet blev -13,1 mkr (-12,2) med intäkter om 5,8 mkr (7,2).
